ReviewMolecular biology reports2026
DNA methylation-mediated regulation of TRAIL pathway components (DR5, DcR2, and CASP3) in breast cancer: molecular mechanisms and therapeutic implications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer and a leading cause of cancer-related mortality among women worldwide. Survival by apoptosis is a mechanism that is key to disease activity and failure to response to therapy. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway has been identified as a therapeutic target as it is capable of selectively inducing apoptosis in cancer cells via death receptors, notably TRAIL receptor-2 (DR5/TNFRSF10B), with subsequent activation of downstream caspases, such as caspase-3. But breast cancer cells can escape TRAIL induced apoptosis by modulating or down-regulating expression of death-receptors, up-regulating expression of decoy-receptors (e.g., DcR2/TNFRSF10D), and regulating the downstream apoptotic regulators. New studies reveal that epigenetic changes, such as DNA methylation, affect genes associated with apoptosis and could be responsible for resistance to TRAIL. This review critically evaluates the latest evidence on epigenetic regulation of important factors of the TRAIL pathway, including DR5 and also DcR2 and caspase-3. The effects of promoter DNA methylation on gene expression, apoptotic signaling, TRAIL resistance and its potential as a clinical prognostic/predictive biomarker are discussed. Data suggest that hypermethylation of the DR5 promoter may lead to the silencing of DR5 and the failure to promote apoptosis through TRAIL, while aberrant methylation of DcR2 may affect apoptotic signals. CASP3 methylation, in turn, can diminish the apoptotic function and cause therapeutic resistance. Taken together, these results identify DNA methylation as a key modulator of TRAIL-mediated killing and provide clues for the identification of potential biomarkers and epigenetic therapeutic approaches to regain apoptotic functions in breast cancer.
Indexed as
Identifiers
42859250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.